Guided Therapeutics Depreciation & Amortization Growth & History (GTHP)
Guided Therapeutics's depreciation and amortization was $10,000 for fiscal 2025.
View full Guided Therapeutics company overviewGuided Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10,000 | $1,000 | +11.11% |
| 2024 | 2024-12-31 | $9,000 | $0 | 0.00% |
| 2023 | 2023-12-31 | $9,000 | $5,000 | +125.00% |
| 2022 | 2022-12-31 | $4,000 | −$79,000 | −95.18% |
| 2021 | 2021-12-31 | $83,000 | $83,000 | — |
| 2020 | 2020-12-31 | $0 | −$21,000 | — |
| 2019 | 2019-12-31 | $21,000 | −$6,000 | −22.22% |
| 2018 | 2018-12-31 | $27,000 | −$186,000 | −87.32% |
| 2017 | 2017-12-31 | $213,000 | −$1.0M | −82.58% |
| 2016 | 2016-12-31 | $1.2M | $169,000 | +16.03% |
| 2015 | 2015-12-31 | $1.1M | −$186,000 | −15.00% |
| 2014 | 2014-12-31 | $1.2M | $779,000 | +168.98% |
| 2013 | 2013-12-31 | $461,000 | $100,000 | +27.70% |
| 2012 | 2012-12-31 | $361,000 | $327,000 | +961.76% |
| 2011 | 2011-12-31 | $34,000 | $27,000 | +385.71% |
| 2010 | 2010-12-31 | $7,000 | — | — |
Guided Therapeutics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2,000 | −$1,000 | −33.33% |
| Q1 2026 | 2026-03-31 | $2,000 | $0 | 0.00% |
| Q4 2025 | 2025-12-31 | $28,000 | — | — |
| Q3 2025 | 2025-09-30 | $2,000 | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $3,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $2,000 | $0 | 0.00% |
| Q3 2024 | 2024-09-30 | $2,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $3,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $2,000 | $0 | 0.00% |
| Q3 2023 | 2023-09-30 | $2,000 | −$16,000 | −88.89% |
| Q2 2023 | 2023-06-30 | $3,000 | −$14,000 | −82.35% |
| Q1 2023 | 2023-03-31 | $2,000 | −$14,000 | −87.50% |
| Q3 2022 | 2022-09-30 | $18,000 | — | — |
| Q2 2022 | 2022-06-30 | $17,000 | — | — |
| Q1 2022 | 2022-03-31 | $16,000 | — | — |
| Q3 2020 | 2020-09-30 | $0 | $0 | — |
| Q2 2020 | 2020-06-30 | $0 | −$16,000 | — |
| Q1 2020 | 2020-03-31 | $0 | −$5,000 | — |
| Q3 2019 | 2019-09-30 | $0 | −$5,000 | — |
| Q2 2019 | 2019-06-30 | $16,000 | $5,000 | +45.45% |
| Q1 2019 | 2019-03-31 | $5,000 | −$1,000 | −16.67% |
| Q3 2018 | 2018-09-30 | $5,000 | −$12,000 | −70.59% |
| Q2 2018 | 2018-06-30 | $11,000 | −$12,000 | −52.17% |
| Q1 2018 | 2018-03-31 | $6,000 | −$31,000 | −83.78% |
| Q3 2017 | 2017-09-30 | $17,000 | −$29,000 | −63.04% |
| Q2 2017 | 2017-06-30 | $23,000 | −$25,000 | −52.08% |
| Q1 2017 | 2017-03-31 | $37,000 | −$17,000 | −31.48% |
| Q3 2016 | 2016-09-30 | $46,000 | −$23,000 | −33.33% |
| Q2 2016 | 2016-06-30 | $48,000 | −$24,000 | −33.33% |
| Q1 2016 | 2016-03-31 | $54,000 | −$18,000 | −25.00% |
| Q3 2015 | 2015-09-30 | $69,000 | $10,000 | +16.95% |
| Q2 2015 | 2015-06-30 | $72,000 | −$111,000 | −60.66% |
| Q1 2015 | 2015-03-31 | $72,000 | −$45,000 | −38.46% |
| Q3 2014 | 2014-09-30 | $59,000 | −$58,000 | −49.57% |
| Q2 2014 | 2014-06-30 | $183,000 | $68,000 | +59.13% |
| Q1 2014 | 2014-03-31 | $117,000 | $5,000 | +4.46% |
| Q3 2013 | 2013-09-30 | $117,000 | $22,000 | +23.16% |
| Q2 2013 | 2013-06-30 | $115,000 | $27,000 | +30.68% |
| Q1 2013 | 2013-03-31 | $112,000 | $37,000 | +49.33% |
| Q3 2012 | 2012-09-30 | $95,000 | $85,000 | +850.00% |
| Q2 2012 | 2012-06-30 | $88,000 | $84,000 | +2100.00% |
| Q1 2012 | 2012-03-31 | $75,000 | $71,000 | +1775.00% |
| Q3 2011 | 2011-09-30 | $10,000 | — | — |
| Q2 2011 | 2011-06-30 | $4,000 | — | — |
| Q1 2011 | 2011-03-31 | $4,000 | — | — |
Guided Therapeutics depreciation and amortization trends
Over the last five fiscal years, Guided Therapeutics's depreciation and amortization increased from $0 to $10,000, a change of $10,000. The latest reported quarter, Q2 2026, shows $2,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Guided Therapeutics source filings ↗